BRIEF

on AMOEBA (EPA:ALMIB)

Amoéba obtains exemptions in the Netherlands for its biocontrol in 2026

Stock price chart of AMOEBA (EPA:ALMIB) showing fluctuations.

Amoéba, a French specialist in microbiological solutions, has obtained two temporary authorizations in the Netherlands for its biofungicide AXPERA. Granted by the CTGB (Technical Committee for Plant Breeding), these two-year exemptions allow trials on several crops, particularly in greenhouses, permitting the consumption of the harvested crops. This market represents a significant opportunity, as the Netherlands is a leader in greenhouse horticulture. The authorizations will cover major crops such as tomatoes, as well as newer ones like potatoes and leeks.

Koppert, a strategic partner of Amoéba, has also received a license to use AXPERA technology, supported by Glastuinbouw Nederland. These initiatives aim to demonstrate the product's effectiveness against persistent diseases such as powdery mildew, while accelerating its validation and adoption in Europe.

R. P.

Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.

Click here to consult the press release on which this article is based

See all AMOEBA news